Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of the ranibizumab Port Delivery System versus monthly intravitreal ranibizumab in Chinese patients with neovascular age-related macular degeneration
CTR20222633Phase 3Active
- Sponsor
- Roche
- Start
- Jun 2024
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ranibizumab in exudative macular degeneration (2 arms), sponsored by Roche. Primary endpoint: Mean change from baseline in BCVA score averaged over Weeks 36 and 40. Started Jun 2024; status: active.
02
Drugs
ranibizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on CTR20222633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222633.